



Review on Inhaler Market in India for Chronic Diseases

Swapnil Zarkar¹ and Dr. S. C. Atram²

Student, Vidyabharti College of Pharmacy, Amravati, Maharashtra, India¹

Assistant Professor, Department of Chemistry, Vidyabharti College of Pharmacy, Amravati, Maharashtra, India²

Abstract: *Asthma is one of the most common chronic non-Communicable diseases in children and adults. Asthma is a disorder characterized by chronic airway inflammation, airway hypersensitivity to a variety of stimuli, and airway obstruction. It is at least partially reversible, either spontaneously or with treatment. An Inhaler is a device that gets medicine directly into a person's lungs. The medicine is a mist or spray that the person breathes in. Unlike a pill or liquid that is swallowed, an inhaler gets medicine right to the lungs. This helps people with asthma because the medicine works quickly to open up narrowed airways. The inhaler market in India is divided into four categories: device, type, application, and end-user. Metered dose inhaler, dry powdered inhaler, and nebulizer are the three device segments that make up the market. The goal of this report is to take a survey about the Inhaler market growth by years and years. Inhalers are developed and sold on a large scale from past few years the inhaler market has booked a profit of 500 million average profit.*

Keywords: Bronchodilator, Oropharyngeal, Catastrophic, Nebulizers, Plethora

REFERENCES

- [1]. <https://www.techsciresearch.com/report/india-respiratory-inhalers-market/7468.html>
- [2]. <https://www.researchandmarkets.com/reports/5530729/india-respiratory-care-devices-market-by-product>
- [3]. Lewis A, Torvinen S, Dekhuijzen PN, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. *BMC Health Serv Res.* 2016; 16:251.
- [4]. Asthma UK. Asthma facts and statistics. Available from: <https://www.asthma.org.uk/about/media/facts-and-statistics/>. Accessed February 12, 2018.
- [5]. World Health Organization. Chronic respiratory diseases. Available from: <http://www.who.int/respiratory/en/>. Accessed October 26, 2017.
- [6]. Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. *J Aerosol Med Plum Drug Deliv.* 2017;30(1):20–41.
- [7]. Newman SP, Weisz AW, Talae N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. *Thorax* 1991; 46: 712–716.
- [8]. Molimard M, Raheison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. *J Aerosol Med* 2003; 16: 249–254.
- [9]. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. *Respir Med* 2000; 94: 496–500.
- [10]. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. *J Aerosol Med* 1996; 9: 55–70.
- [11]. Asthma.org.uk. (2020). Smart inhalers. Retrieved on 12/28/2020 from: <https://www.asthma.org.uk/advice/inhalers-medicines-treatments/inhalers-and-spacers/smart-inhalers/>



- [12]. Mohammadi, D. (2017). Smart inhalers: will they help to improve asthma care? *The Pharmaceutical Journal*. Retrieved on 12/28/2020 from: <https://www.pharmaceutical-journal.com/news-and-analysis/features/smart-inhalers-will-they-help-to-improve-asthma-care/20202556.article>
- [13]. Blakey, J. D. et al. (2018). Digital technologies and adherence in respiratory diseases: the road ahead. *European respiratory journal*. <https://dx.doi.org/10.1183%2F13993003.01147-2018>. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364097/>
- [14]. Van Boven, J. F. M. et al. (2018). Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. *npj Primary care respiratory* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021429/>
- [15]. <https://www.verywellhealth.com/breath-actuated-metered-dose-inhaler-201191>
- [16]. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication delivery systems. *Chest* 1993; 104: 1737–1742.
- [17]. Crompton GK. Problems patients have using pressurized aerosol inhalers. *Eur J Respir Dis Suppl* 1982; 119: 101–104.
- [18]. Pedersen S, Ostergaard PA. Nasal inhalation as a cause of inefficient pulmonary aerosol inhalation technique in children. *Allergy* 1983; 38: 191–194.
- [19]. Lindgren S, Bake B, Larsson S. Clinical consequences of inadequate inhalation technique in asthma therapy. *Eur J Respir Dis* 1987; 70: 93–98.
- [20]. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *Eur Respir J* 2002; 19: 246–251.
- [21]. Hochrainer D, Ho lz H. Comparison of the aerosol velocity and spray duration of Respimat1 Soft Mist™ inhaler and pressurised metered dose inhalers. *J Aerosol Med* 2005; 18: 273–282.
- [22]. O'Callaghan C, Wright P. The metered-dose inhaler. In: Bisgaard H, O'Callaghan C, Smaildone GC, eds. *Drug Delivery to the Lung*. New York, Marcel Dekker, 2002; pp. 337–370.
- [23]. Newman SP, Pavia D, Clarke SW. How should a pressurized beta-adrenergic bronchodilator be inhaled? *Eur J Respir Dis* 1981; 62: 3–21.
- [24]. Hindle M, Newton DA, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. *Thorax* 1993; 48: 607–610.
- [25]. Connolly CK. Method of using pressurized aerosols. *BMJ* 1975; 3: 21.
- [26]. Epstein SW, Manning CP, Ashley MJ, Corey PN. Survey of the clinical use of pressurized aerosol inhalers. *Can Med Assoc J* 1979; 120: 813–816.
- [27]. Shim C, Williams MH Jr. The adequacy of inhalation of aerosol from canister nebulizers. *Am J Med* 1980; 69: 891–894.
- [28]. Kelling JS, Strohl KP, Smith RL, Altose MD. Physician knowledge in the use of canister nebulizers. *Chest* 1983; 83: 612–614.
- [29]. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005; 127: 335–371.
- [30]. Derom E, Thorsson L. Factors affecting the clinical outcome of aerosol therapy. In: Bisgaard H, O'Callaghan C, Smaildone GC, eds. *Drug Delivery to the Lung*. New York, Marcel Dekker, 2002; pp. 143–171.
- [31]. van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. *Patient Educ Couns* 1997; 32: S87–S95.
- [32]. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. *Respir Med* 2005; 99: 97–102.



- [33]. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery V. Buffalo Grove, Interpharm Press, 1996; pp. 115–123.
- [34]. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers-into the new millennium. Int J Pharm 2000; 201: 89–107